Effects of Self-Conditioning Techniques (Self-Hypnosis) in Promoting Weight Loss in Patients with Severe Obesity: A Randomized Controlled Trial by Bo, S et al.
 
 
1 
 
Effects of self-conditioning techniques (self-hypnosis) in promoting weight loss in 1 
patients with severe obesity: a randomized controlled trial.   2 
Simona Bo1*, Farnaz Rahimi2, Ilaria Goitre1, Bice Properzi3, Valentina Ponzo1, Giuseppe 3 
Regaldo4, Stefano Boschetti2, Maurizio Fadda2, Giovannino Ciccone5, Giovanni Abbate 4 
Daga6, Giulio Mengozzi7, Andrea Evangelista5, Antonella De Francesco2, Sara Belcastro1, 5 
Fabio Broglio1         6 
1Department of Medical Sciences, University of Turin, Turin, Italy, 2 Unit of Clinical Nutrition, Città della Salute e della Scienza, Hospital of 7 
Turin, Turin, Italy 3 Unit of Internal Medicine, Città della Salute e della Scienza, Hospital of Turin, Turin, Italy 4 Obstetric Department, 8 
Hospital of Ciriè, Turin, Italy 5 Unit of Clinical Epidemiology, CPO, Città della Salute e della Scienza Hospital of Turin, Turin, Italy 6 9 
Division of Psychiatry, Department of Neurosciences, University of Turin, Turin, Italy 7Clinical Biochemistry Laboratory, Città della Salute 10 
e della Scienza, Hospital of Turin, Turin, Italy 11 
*Corresponding author: Simona Bo, Department of Medical Sciences, University of Turin, 12 
Corso Dogliotti 14, 10126 Turin, Italy; Telephone +39(0)116336036    Fax+39(0)116335401   13 
E-mail: simona.bo@unito.it 14 
Keywords: C-reactive protein, obesity, randomized controlled trial, self-hypnosis 15 
Running title: self-hypnosis in obesity 16 
Word Count: 3999 text, 2 tables, 1 figure 17 
Conflicts of interest statement: The authors report no conflict of interest.  18 
Funding: This study was supported by a grant from the Ministry of Education, University 19 
and Research of Italy (ex-60% 2014). 20 
Trial Registration: The trial was registered at www.clinicaltrials.gov  (identifier 21 
NCT02978105). 22 
What is already known about this subject?  23 
• Overeating often involves loss of control and compulsive behaviors 24 
• Hypnosis has been suggested as an effective tool for weight reduction 25 
• The hypnotic techniques previously employed were long, demanding, and difficult to be performed in 26 
clinical practice on a large number of patients 27 
 28 
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What does this study add? 29 
• Self-hypnosis added to a lifestyle intervention was effective in ameliorated satiety, quality of life, and 30 
inflammation 31 
• Individuals who used more frequently self-hypnosis lost more weight and greatly reduced their caloric 32 
intake 33 
• Self-hypnosis was safe and the obtained results were independent of the susceptibility to hypnosis 34 
Abstract  35 
Objectives: The usefulness of the rapid-induction techniques of hypnosis as adjunctive 36 
weight-loss treatments is not defined. This randomized controlled trial evaluated whether self-37 
conditioning techniques (self-hypnosis) added to lifestyle interventions were effective in 38 
determining weight-loss, changes in metabolic/inflammatory variables, and quality-of-life 39 
(QoL) improvement with respect to traditional lifestyle approaches in severe obesity. 40 
Methods: Individuals (BMI=35-50kg/m2) without organic/psychiatric comorbidity were 41 
randomly assigned to the intervention (n=60) or control arm (n=60). All received 42 
exercise/behavioral recommendations and individualized diets. The intervention consisted of 3 43 
hypnosis sessions, during which self-hypnosis was taught to increase self-control before 44 
eating. Diet, exercise, satiety, QoL, anthropometric measurements, blood variables were 45 
collected/measured at enrolment and at 1-year (trial-end). Results: Participants reduced their 46 
caloric intake and lost weight, without significant between-group difference (-423.8kcal, -47 
6.5kg intervention arm; -379.0kcal, -5.6kg controls). However, habitual self-hypnosis users 48 
lost more weight (-9.6kg; β=-10.2; 95%CI -14.2 -6.18; p<0.001) and greatly reduced their 49 
caloric intake (-682.5kcal; β=-643.6; -1064.0 -223.2; p=0.005) in linear regression models. At 50 
trial-end, intervention group showed lower C-reactive protein values (β=-2.55; -3.80 -1.31; 51 
p<0.001), higher satiety (β=19.2; 7.71 30.6; p=0.001) and better QoL (β=0.09; 0.02 0.16; 52 
p=0.01). Conclusions: In severe obesity, self-hypnosis ameliorated satiety, QoL, 53 
inflammation, and determined greater weight loss in more frequent users.  54 
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Introduction 55 
Due to the rising epidemic of obesity, little success and high rates of relapse of its treatment, 56 
the finding of new approaches for its care has become increasingly important.  57 
In the past, some studies have evaluated the effectiveness of hypnosis as an adjunctive 58 
therapy for weight loss (1-3).  Clinical hypnosis is a procedure in which changes in sensation, 59 
perception, thought and behavior are suggested by a therapist; the hypnotic induction 60 
produces either “a distinct state of consciousness” or a normal state with heighten 61 
suggestibility according to the different theoretical conceptions of hypnosis (1,4).  62 
Overall, hypnosis has been recognized as an effective tool for weight reduction, even if many 63 
methodological limitations of the published research (small cohorts, lack of long-term follow-64 
up, variations in procedures, different response measurements) have been identified, making 65 
the evaluation of treatment efficacy difficult (5).  Usually, traditional hypnotic techniques 66 
were combined with social, cognitive and behavioral psychological approaches. The hypnotic 67 
procedure used varied greatly among studies, ranging e.g. from a 9-weeks program, with the 68 
presentation of eating and dieting rules during the hypnotic sessions (6), a total 24-h hypnotic 69 
treatment with a therapist, and the successive utilization of audiotapes (7), to a combination of 70 
hypnotic and behavioral therapy for twelve 120-min sessions over a period of 8.5-months (8), 71 
a multifaceted program with suggestions for relaxation, self-control, self-esteem, 72 
strengthening motivation towards change (9). Most of these treatments are long, demanding, 73 
and difficult to be performed in clinical practice on a large number of patients. Moreover, 74 
during the hypnotic sessions many researchers gave suggestions targeting aversion to specific 75 
high-calorie foods, persuading that overeating is a poison, or employing other techniques of 76 
aversion (10-11), rather than purposeful messages or pleasant suggestions for heightening the 77 
awareness of self-control and healthy functioning.  78 
 
 
4 
 
Recently, techniques with a rapid-induction phase allow the patient to go into hypnosis in a 79 
few minutes. Trained individuals can repeat the experience in complete autonomy (self-80 
hypnosis), using little time of the day.  81 
Overeating often involves loss of control and compulsive behaviors (12), and frequently 82 
people bring with themselves the daily stress and worries during meals, thus eating in less 83 
conscious ways and consuming more calories than necessary.  84 
We hypothesized that self-hypnosis could be applied before eating occasions or circumstances 85 
of irrational food need, as an aid to increase awareness and self-control. 86 
Therefore, our aims were evaluating whether in patients with severe obesity self-conditioning 87 
techniques (self-hypnosis) added to traditional lifestyle approach (diet, exercise and 88 
behavioral recommendations) were effective in determining weight loss, changes in metabolic 89 
and inflammatory variables, and improvement in the quality of life, with respect to the 90 
traditional lifestyle approach. 91 
 92 
Methods 93 
The methods of the present trial have been previously reported (13). The trial was conducted 94 
at the Unit of Clinical Nutrition of the “Città della Salute e della Scienza” Hospital of Turin, 95 
Italy. Participants were enrolled between January 2015-June 2016.  96 
Inclusion criteria were: BMI 35-50 kg/m2; age 20-70 years; being able to give written 97 
informed consent and accepting hypnosis. The exclusion criteria were: current/previous 98 
mental disorders diagnosed by an expert clinician and/or use of any psychotropic drug; insulin 99 
treatment; candidates to bariatric surgery; current (or discontinued for <6-months) treatment 100 
with anti-obesity drugs; at risk of heart failure, edema, ascites (known heart diseases, chronic 101 
liver diseases, nephrotic syndrome, renal failure; untreated or uncompensated thyroid 102 
diseases). Before enrolment, in order to exclude clinically relevant psychiatric symptoms 103 
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below diagnostic thresholds, patients were submitted to the following questionnaires: the 104 
Hamilton rating scale for depression (14), the Hamilton anxiety scale (15), and the Binge 105 
Eating Scale (16). Only individuals who satisfied all the three scores (respectively <8, <17 106 
and <17) were considered for enrolment. 107 
This prospective, randomized controlled, open-label monocentric trial was registered at 108 
ClinicalTrials.gov (identifier NCT02978105). 109 
Intervention 110 
Eligible patients were randomized either to the experimental arm (self-conditioning 111 
techniques plus standard care) or the control arm (standard care, i.e. diet plus exercise plus 112 
behavioral recommendations) (Figure 1). 113 
All the participants received a personalized diet by a trained dietician (energy 114 
~1500±100kcal/day, 15-20% protein, 55-60% carbohydrates, 25-30% lipids), and the 115 
recommendation of performing at least 20-minutes/day of brisk walking, according to the 116 
Borg scale criteria (17). Verbal and written behavioral recommendations were given to all 117 
patients, i.e. recommendations about exercise inclusion in daily activities and simple tips to 118 
favor diet adherence (i.e. don't buy foods on an empty stomach, do not do anything else when 119 
eating, etc). 120 
The participants were followed-up every 3-months (at 3,6,9, and 12-months after enrolment) 121 
by a dietician and a medical doctor, and a physical assessment, the recording of adverse 122 
events or effects, and a check of compliance to the protocol were performed. During visit 123 
intervals (at 1.5, 4.5, 10.5-months after enrollment), participants were called by phone and 124 
asked about adverse events and compliance to the intervention.  125 
Subjects who withdrew from the study before 12-months for any reasons or those who during 126 
the trial took slimming products/drugs or employed techniques to lose weight other than those 127 
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recommended (e.g. very-low-calorie diets, or highly unbalanced diets) were considered as 128 
drop-outs. 129 
Self-hypnosis 130 
The experimental group received three individual sessions of hypnosis, performed by trained 131 
personnel (2 nurses, 1 medical doctor). To minimize the potential lack of fidelity, the health 132 
care providers were assigned to the sessions by a scheduled rotation among sessions to ensure 133 
a balanced intervention. Rapid-induction techniques were used, and the patient went into a 134 
hypnotic condition in a few minutes (18). 135 
Timing of the hypnosis sessions was after 2-weeks, 6-weeks, and 15-weeks from 136 
randomization (13). The first session of the hypnotic procedure (lasting about 30-minutes) 137 
was briefly introduced, and information about medical hypnosis and its potential application 138 
as an amplification of personal resources to manage self-control were given. During this 139 
phase, the degree of susceptibility to hypnosis was evaluated by the eyeroll test of Spiegel 140 
(19). Thereafter, the rapid hypnotic induction was determined through a technique of attention 141 
focusing (fixing a point or focusing the attention on a part of one’s body) and ratification of 142 
what was happening; the following were the phases of full-body relaxation, of slow breathing, 143 
of imagining pleasant images and thoughts and creating an ideal "safe place" where the 144 
subject could take refuge. In this imaginary place, the subject could feel stronger, more 145 
determined, self-controlled, efficient, and able to sit at table aware of what he/she was about 146 
eating, refraining from gorging. The last phase was the anchor phase, during which the 147 
subject received a self-conditioning symbolic signal (i.e. joining the thumb with index or 148 
making the fist with the thumb folded inside the hand) by which he/she could rapidly fall 149 
under hypnosis in complete autonomy (self-hypnosis), also repeatedly during the day. The 150 
anchor stage was then checked and if necessary the procedure was repeated a second and/or 151 
third time by changing suggestions and/or the symbolic anchor signal. Finally, instructions 152 
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were given about self-hypnosis use before each meal or food-compulsion occasion for about 153 
3-minutes (10-seconds to enter, 2-minutes of “safe place” thinking with muscle relaxation and 154 
mental well-being, and 30-seconds to exit). 155 
In the subsequent two sessions (“reinforcements sessions”) lasting 20-30-minutes, participants 156 
reported difficulties, problems, barriers and benefits with self-hypnosis. The skill of going 157 
into hypnosis was checked again. The same suggestions of the first session were employed, 158 
and a new image was evoked to reinforce the skill to face difficulties (a metaphorical climb 159 
on a mountain top by overcoming natural obstacles). Finally, suggestions for overcoming the 160 
encountered barriers and problems were given. 161 
The hypnotic sessions had a common core, but the way of hypnosis induction was 162 
individualized based on the participants’ characteristics.  163 
Quality control 164 
The participants’ acquired skills were checked during each session by the hypnotists by the 165 
evaluation of typical muscle changes (muscle inertia, levitation, catalepsy), characteristic 166 
physical appearance (variation of facial expression, movements of eyelids/eyeballs, 167 
swallowing, changes in respiratory rate, vasodilation), alteration of consciousness (partial 168 
detachment from reality, time warp, realistic images and conceived situations). The hypnotic 169 
condition achieved was considered satisfactory if all the above reported conditions were 170 
present at the same time.  171 
In the case of a low hypnotizability, the participant was still encouraged to run the procedure 172 
before each meal and food compulsion attack. 173 
Outcomes 174 
The primary outcome was the between-arms weight change at 12-months after randomization. 175 
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Secondary outcomes were between-arms changes in waist circumference, arterial blood 176 
pressure, metabolic/inflammatory variables, satiety, well-being, and eating and exercise 177 
pattern. 178 
Randomization 179 
The list of randomization, stratified by age (50; >50 years), gender, and BMI (40; >40 kg/m2) 180 
was generated by a variable-length block procedure, masked to researchers. The 181 
randomization procedure was centrally run through an online procedure (available at: 182 
http://www.epiclin.it). A unique code was assigned to each participant.  183 
Blinding 184 
Blinding participants and health professionals was not possible, owing to the nature of the 185 
intervention. Indeed, the personnel who performed the laboratory analyses, the 186 
anthropometric measurements, and collected questionnaire data was blinded to the arm 187 
assignment. 188 
Safety 189 
Adverse events and compliance with the study protocol was monitored both during each visit 190 
and between the visits (by phone calls). Participants were instructed to inform the researchers 191 
if adverse effects occurred. 192 
Ethics 193 
The study protocol received ethical approval from the local ethics committee. All the 194 
procedures were conducted according to the Helsinki Declaration. All patients provided their 195 
written informed consent to participate. 196 
Measurements 197 
At enrolment and at 12-months (trial end), all the participants were submitted to the 198 
following: 199 
-3-day food record  200 
 
 
9 
 
-the Minnesota-Leisure-Time-Physical-Activity questionnaire (20) 201 
-The Satiety Labeled Intensity Magnitude scale (21) 202 
-The Satisfaction and well-being (EuroQol (EQ)-5 questionnaire [Index and Visual Analog 203 
Scale (VAS)] (22) 204 
-anthropometric and arterial blood pressure measurements  205 
-blood sample collections after an overnight fast to measure glucose, insulin, glycated 206 
hemoglobin (HbA1c), total and HDL-cholesterol, triglycerides, and high-sensitivity C-207 
reactive protein (CRP).   208 
Body weight and waist circumference were measured at 3, 6, 9-months from randomization, 209 
too.  210 
Participants from the intervention arm were asked about the frequency of self-hypnosis use; 211 
they were divided in individuals with low (0-1), medium (2-3), or high hypnotizability (4) 212 
according to the score obtained by the eyeroll Spiegel test. 213 
The physical activity level was calculated as the product of the duration and frequency of each 214 
activity (hours/week), weighted by an estimate of the metabolic equivalent (MET) of the 215 
activity and summed for the activities performed (20). 216 
Body weight was measured to the nearest 0.1kg, and height to the nearest 0.1cm by a 217 
stadiometer (SECA model 711, Hamburg, Germany), with the participants wearing light 218 
clothes and no shoes. Waist circumference was determined by a plastic meter at the highest 219 
point of the iliac crest. Body composition was assessed by Dual-energy X-ray absorptiometry 220 
(DXA) (QDR-4500; Hologic, Bedford, MA, USA), using whole-body absorptiometry 221 
software. 222 
Arterial blood pressure was measured by a mercury sphygmomanometer with appropriate cuff 223 
sizes (ERKA Perfect-Aneroid, Germany) in a sitting position after at least 10-min rest; the 224 
values reported were the mean of two measurements. 225 
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Laboratory methods have been previously published (13). Homeostasis Model Assessment-226 
Insulin Resistance (HOMA-IR) was calculated according to the published algorithm (23). 227 
Statistical analyses 228 
The sample size was calculated in relation to the primary outcome. Available data on patients 229 
with clinical characteristics similar to those enrolled were used. With an effect size=0.67 and 230 
a 2-tailed α-error=0.05, 48 patients per arm were needed to obtain a 90% power. This number 231 
was increased to 60, because of the possibility of drop-outs. 232 
Endpoints analyses were based on the between-arms comparisons of the changes from 233 
baseline to 12-months after randomization (deltas). Linear regression models were used to 234 
compare deltas of the analyzed endpoints between-arms, adjusting for the baseline 235 
measurement and the randomization stratification variables [gender, age (50; >50 years), BMI 236 
(40; >40 kg/m2)].  237 
An intention-to-treat analysis was performed including all the randomized patients by 238 
multiple imputing missing 12-month variables, using the method of chained equations (24). 239 
Combined estimates were obtained from 50 imputed datasets. 240 
For each randomization arm, mean changes from baseline for weight, BMI and waist 241 
circumference were estimated at 3, 6, 9 and 12-months using linear regression models for 242 
repeated measures. Interaction terms between-arms and the time point variables were included 243 
to estimate the specific mean change from baseline for each arm at fixed times. To account for 244 
the repeated measures on the same subject, mean changes from baseline were estimated 245 
controlling the standard errors with the Huber-White Sandwich Estimator (25).   246 
The associations between hypnosis use frequencies (coded as dummy variables) and 247 
anthropometric/laboratory variables, and questionnaire scores were evaluated by linear 248 
regression models, adjusted for the randomization stratification variables. 249 
 250 
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Results 251 
At 12-months, there were 16/60 (26.7%) individuals lost at follow-up from the intervention 252 
arm and 18/60 (30.0%) from the control arm.  The main reasons for drop-outs are reported in 253 
Figure 1. No adverse event was recorded. During the trial, no death or hospitalization 254 
occurred. 255 
No significant difference was evident between individuals who completed the trial and those 256 
who were lost, even if the latter tended to be younger and more frequently males 257 
(Supplementary-Table 1).   258 
The clinical and laboratory characteristics at enrolment were very similar between the two 259 
randomization arms (Table 1).  260 
Changes in lifestyle habits and drug use 261 
Mean energy intakes significantly decreased in both groups at follow-up (respectively, in the 262 
intervention and control arms: 1470.6±281.1 and 1496.9±311.9kcal; p<0.001 for within-group 263 
difference in both groups). Mean differences were -423.8 and -379.0kcal respectively in the 264 
intervention and control arm (p=0.84). The composition in macronutrients did not 265 
significantly change from baseline to the trial end in both arms (data not shown). 266 
Median (interquartile range) METs values at follow-up were 24.8 (27.2) and 30.5 (41.7) 267 
h/week in the intervention and control arms respectively, without significant difference in 268 
within and between-group analyses.  269 
During follow-up, there were small variations in the therapy of the patients: hypoglycemic 270 
drugs were added to 2 and 1 subjects respectively from the intervention and control arms, 271 
lipid-lowering agents were added to 1 subject from both arms, antihypertensive drugs were 272 
suspended to 1 subject from the intervention arm and added to 1 control.  273 
Changes in anthropometric and laboratory variables 274 
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Individuals from the two arms significantly reduced their weight, BMI, and waist 275 
circumference values from baseline to the trial end (Supplementary-Table 2). Within-group 276 
variations were significantly different as early as 3-months after randomization. 277 
Changes in anthropometric and laboratory variables are reported in Table 2. Deltas (end-of 278 
the trial values – baseline values) did not differ between-arms, with the exception of delta 279 
CRP values which significantly decreased in the intervention arm. 280 
Intention-to treat analyses confirmed the significant reduction in CRP values in the 281 
intervention arm (Supplementary-Table 3). 282 
Changes in satiety, and health status 283 
Participants from the intervention arm showed increased scores of satiety and quality of life at 284 
the trial end (Table 2), with within-group significant differences (respectively, p=0.001, 285 
p<0.001 and p=0.002 for satiety, EuroQoL VAS, and EuroQoL health status). In the controls, 286 
these scores did not change significantly. The associations between being in the intervention 287 
arm and the scores were confirmed by linear regression (Table 2), and by the intention-to-treat 288 
analyses (Supplementary-Table 3). 289 
Frequency of self-hypnosis use 290 
At the trial end, 16/44 (36.3%) declared to practice self-hypnosis regularly once/day, 7/44 291 
(15.9%) more frequently than once/day, 9/44 (20.5%) less frequently than once/day, i.e. with 292 
a weekly frequency, but 12/44 (27.3%) rarely or never. The corresponding values of delta 293 
weight were: -9.6kg (≥once/day), -7.5kg (<once/day), and +0.2 (rarely or none). 294 
The frequency of hypnosis use was significantly associated with changes in weight, BMI, 295 
waist circumference, and energy intake, after adjusting for age, gender, and BMI 296 
(Supplementary-Table 4). No significant association was evident with the other 297 
anthropometric and laboratory variables, or questionnaire scores. 298 
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The frequency of self-hypnosis declined with time. The prevalence of individuals practicing 299 
the procedure respectively ≥once/day, <once/day and rarely/none was 77.8%, 15.6%, 6.7% at 300 
6 months and 72.7%, 15.9%, 11.4% at 9-months.  301 
Hypnotizability 302 
Participants in the intervention arm were divided according to the eyeroll test of Spiegel in 303 
individuals with low (43.2%), medium (52.3%), or high hypnotizability (4.5%) (19). 304 
No difference in the hypnotizability scores was evident between individuals who completed 305 
or not the follow-up (Supplementary-Table 1). The susceptibility to hypnosis did not correlate 306 
with any outcomes, either the anthropometric and laboratory variables or the scores of the 307 
analyzed questionnaires. 308 
 309 
Discussion 310 
The use of self-hypnosis was associated with a significant between-group difference in the 311 
quality of life, satiety score, and CRP values, but not with changes in the anthropometric 312 
variables. In the intervention arm, however, the increased frequency of self-hypnosis use 313 
correlated with increased reduction in body weight, and energy intakes. 314 
Changes in anthropometric variables 315 
Literature reports that hypnosis leads to variable weight loss at 6-months with a difference 316 
ranging from 4 to 8 kg between the groups with and without hypnosis (2,6-7). Hypnosis has 317 
been reported to be successful not by itself as a treatment for obesity, but as a facilitator of a 318 
specific lifestyle intervention, by increasing the patient involvement in the therapeutic process 319 
(6). Therefore, usually hypnosis has been combined with behavioral approaches, and most of 320 
these treatments are long-lasting, complex, challenging, and, therefore, difficult to be 321 
performed routinely (6-9).  322 
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Our hypnotic approach had the advantage to be rapid and our intervention was less 323 
demanding and easier to be implemented in the clinical practice. However, we did not find 324 
any significant differences between arms in the change of anthropometric variables. 325 
Accordingly, a less-intensive hypnosis program, like ours, led to a lower difference in weight 326 
loss between groups, i.e. <1kg difference (26). Nevertheless, our participants from the 327 
intervention arm who used more frequently (≥once/day) self-hypnosis showed a much greater 328 
weight loss (with an adjusted mean difference of ~10kg), and reduction in energy intake when 329 
compared to those practicing rarely or not at all.  330 
We should take into consideration the fact that after 12-months, only 52% of the participants 331 
practiced self-hypnosis ≥once/day, with a trend towards a progressive reduction of use with 332 
time. Indeed, the reported average use of hypnosis programs in the medium term (>6 months) 333 
was similar to ours (6). 334 
The impact of hypnosis has been reported to increase over time, being more effective in the 335 
long-term, since it allows the establishment of a reinforcement in healthy behaviors that 336 
continues beyond the training period (1,6,27). Weight maintenance requires continued 337 
motivation and engagement; the use of a reinforcement incentive tool, such as self-hypnosis, 338 
might be a motivational successful strategy in promoting the maintenance of weight change. 339 
Accordingly, a significant weight loss compared to baseline at 18-months (27) or a weight 340 
loss of 10kg at 2-years (6) was reported by the few studies evaluating the long-term effects of 341 
hypnosis. 342 
Changes in quality of life and satiety score  343 
Both quality of life and satiety increased in our intervention arm. These changes were not 344 
associated with the frequency of self-hypnosis use. 345 
Accordingly, satisfaction was reported to be greater in the hypnosis arms of the trials (6), and 346 
only the hypnotherapy aimed at reducing stress, but not the one that induced a negative 347 
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attitude towards food, was effective in determining a significant weight loss with respect to 348 
baseline (26). Differently from other studies which employed techniques inducing fear/hate 349 
towards eating and showing some foods as a body poison (10-11,27), we referred to methods 350 
of “ego strengthening” and esteem-enhancement suggestions, with the objective to reduce 351 
stress, and possibly emotional eating, by increasing awareness of self-control and conscious 352 
eating. Our results suggest that the improvement in patients' belief in their capacity of 353 
controlling events might play adjunctive benefits. Furthermore, typical hypnotic inductions 354 
closely resemble conventional relaxation training (1). Therefore, the finding of a better quality 355 
of life in those who have been subjected to hypnosis is not unexpected. Furthermore, our 356 
approach might have strengthened individual self-efficacy, whose increase correlates with 357 
weight loss, and favorably modulates eating behavior and food compulsivity (28). 358 
Finally, even if individuals from both arms similarly reduced their energy intakes, satiety was 359 
significantly increased only in the intervention arm. This is in line with the known modulation 360 
of appetite and satiation associated-peptides and hormones levels through psycho-neuro-361 
immuno- and psycho-neuro-endocrine mechanisms, even in the absence of substantial weight 362 
loss (5,26).  363 
Change in CRP values 364 
Participants from our intervention arm showed a significant reduction in CRP values, the most 365 
commonly used acute-phase reactant marker of inflammation. This finding is intriguing and 366 
suggests a complicate relationship between the mind and the body. It is well known that 367 
distress and quality of life are associated with inflammation and immunologic measures, and 368 
chronic, systemic inflammation has been proposed as one mechanism underlying psychologic 369 
and physical health problems (29-32). Higher levels of psychological distress have been 370 
associated with increased circulating values of CRP and other inflammatory variables though 371 
pathways including the sympathetic nervous system, and the hypothalamic-pituitary-adrenal 372 
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axis (32-34), and the associations between psychological distress and chronic age-related 373 
diseases and mortality might be modulated at least in part by inflammation, as well as other 374 
conditions, such as immunological factors, or dysregulated hormonal responses (35). Our 375 
results could have clinical implications, owing to the chronic sub-clinic inflammatory state of 376 
the individuals with obesity, and the predictive role of chronic inflammation towards 377 
cardiovascular diseases, frailty, disability, and mortality (36-37). 378 
Hypnotic susceptibility 379 
Hypnotizability was not a significant predictor of weight loss or other outcomes in our 380 
patients, in line with some studies and a recent meta-analysis (7,38-39), but differently from 381 
others showing a significant relationship between hypnotic susceptibility and weight loss 382 
outcomes (10,40-41). 383 
Indeed, methods of evaluating the degree of susceptibility to hypnosis varied greatly, and its 384 
assessment has been criticized, since correlations between hypnotizability and treatment 385 
outcome might be indicators of expectancy effects, rather than effects of some special 386 
hypnotic process (1,5). Furthermore, other studies aimed at inducing deeper changes at the 387 
cognitive-behavioral level, with numerous long-lasting hypnosis sessions requiring a high 388 
capacity for trance; therefore, hypnotic abilities can assume greater importance (10,40). 389 
Contrariwise, our short-term sessions of self-hypnosis were aimed at obtaining a brief 390 
moment of relaxation, during which each participant could evoke the suggestion that he/she 391 
would be able to control the amount of food subsequently eaten. Therefore, it is reasonable 392 
thinking that the frequency of use of self-hypnosis was more important than the degree of 393 
susceptibility in our patients. 394 
Finally, we have chosen a very simple measure for pretesting for hypnotizability, since other 395 
complex and time-requiring tests have been considered even counterproductive, because such 396 
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methods could take more time than the therapy, creating concern or irritation in the patient 397 
(39).  398 
Limitations 399 
The main limitation of this trial was the high percentage of drops-out (28%). Other hypnosis 400 
studies reported higher drop-out rates (6,27,42), and >50% of patients with obesity, above all 401 
the youngest, discontinued treatment in clinical practice (43). Furthermore, we took care of 402 
performing an accurate intention-to-treat analysis with imputation of missing values, and 403 
results did not change meaningfully. 404 
The number of patients who completed the intervention was smaller than that originally 405 
defined to obtain an adequate sample size. However, rather than to a reduced power, the lack 406 
of statistical significance of some between-arm comparisons might be attributable to the effect 407 
size found which was smaller than that expected. 408 
We used a very simple approach with three sessions of about 30-minutes each, the last of 409 
which was at 15-weeks after randomization. Therefore, the participants remained 410 
approximately 8-months without receiving any reinforcement session. Accordingly, we 411 
observed a decline in the use of self-hypnosis with time. We cannot exclude that a more 412 
intensive intervention could have resulted in a greater between-arms difference in the 413 
outcomes. However, our goal was to test a simple method, easily applicable to the largest 414 
possible number of individuals in the clinical practice. 415 
Assessments of the quality of life and satiety were highly subjective, and the knowledge of 416 
the study arm might have influenced the participants' responses. However, there was 417 
biological plausibility in the associations found. Furthermore, CRP, a variable associated with 418 
overall distress and blindly measured, was found to be significantly associated with the 419 
intervention arm. Finally, we failed to assess other aspects, such as attitude towards hypnosis 420 
and sleep quality, which could represent potential confounding factors. 421 
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Conclusions 422 
Self-hypnosis is a non-invasive intervention, free of side effects, which ameliorated satiety, 423 
quality of life and CRP values after 12-months. Both the cost-benefit balance of this 424 
procedure and further trials in larger samples should be performed, before final conclusions 425 
about its benefits could be drawn.  426 
 427 
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Table 1. Baseline characteristics of the patients 
 Intervention 
arm 
Control arm Total 
Number 60 60 120 
Age (years) 49.0±12.7 49.0±13.0 49.0±12.8 
Males (%) 33.3 30.0 31.7 
Actual smokers (%) 20.0 21.7 20.8 
METS (h/week) 24.5 (28.1) 28.3 (38.0) 25.6 (32.6) 
Height (m) 1.64±10.2 1.63±9.6 1.63±9.9 
Weight (Kg) 110.7±17.1 108.6±16.7 109.6±16.9 
BMI (Kg/m2) 41.2±4.7 41.0±3.8 41.1±4.3 
Waist circumference (cm) 122.0±12.5 121.0±11.5 121.5±12.0 
Percent body fat 45.3±4.6 45.0± 6.1 45.1±5.4 
Systolic blood pressure (mmHg) 130.2±16.1 130.8±13.6 130.5±14.8 
Diastolic blood pressure (mmHg) 81.5±10.6 81.5±8.3 81.5±9.5 
Dietary intakes    
Energy (kcal) 1872.6±589.2 1875.1±466.7 1873.8±529.2 
Carbohydrates (% total kcal) 48.8±7.0 47.7±8.1 48.3±7.5 
Sugars (% total kcal) 12.1±3.9 11.3±5.1 11.7±4.5 
Proteins (% total kcal) 16.6±2.7 16.5±3.0 16.5±2.9 
Total fats (% total kcal) 33.5±5.4 34.7±7.0 34.1±6.3 
Saturated fatty acids (% total kcal) 9.6±2.6 9.7±2.8 9.6±2.7 
Polyunsaturated fats (% total kcal) 7.5±1.8 7.8±2.1 7.6±1.9 
Fiber (g/day) 17.1±5.2 17.3±5.3 17.2±5.2 
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Mean ± SD, median (interquartile range) 
 
 
 
 
 
Laboratory variables    
Fasting glucose (mg/dL) 94.1±20.2 91.3±17.9 92.7±19.0 
Glycated hemoglobin (mmol/mol) 41.4±8.9 40.2±6.8 40.8±7.9 
Fasting insulin (μU/mL) 14.0 (6.7) 13.8 (11.4) 14.0 (8.5) 
HOMA-IR (mmol/l*µU/mL) 3.1 (2.0) 3.4 (2.8) 3.2 (2.4) 
CRP (mg/L) 5.3 (5.4) 5.4 (7.1) 5.3 (6.4) 
Total cholesterol (mg/dL) 185.8±41.0 186.4±24.7 186.1±33.7 
HDL-cholesterol (mg/dL) 49.8±13.4 47.1±12.2 48.4±12.8 
Triglycerides (mg/dL) 105.5 (55.0) 111.5 (56.0) 96.5 (49.0) 
Drugs    
Antihypertensive (%) 46.7 43.3 45.0 
Hypoglycemic agents (%) 6.7 5.0 5.8 
Lipid lowering (%) 13.3 11.7 12.5 
Questionnaires    
Satiety score 50 (50) 50 (40) 50 (60) 
EuroQoL VAS 61.8±16.3 64.2±17.3 63.0±16.8 
EuroQoL health status 0.67±0.21 0.72±0.14 0.70±0.18 
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Table 2. End-of the trial values of variables and comparisons between arms by a linear regression model 
 Intervention arm Control arm    
 End-of the trial 
value 
Mean 
delta 
End-of the trial 
value 
Mean 
delta 
Adjusted 
mean 
difference 
on delta (β)* 95%CI P 
Weight (Kg) 102.9±16.3 -6.5 100.8±18.6 -5.6 -0.45 -3.78; 2.88 0.79 
BMI (Kg/m2) 38.7±5.0 -2.4 38.8±5.5 -2.1 -0.24 -1.49; 1.01 0.70 
Waist circumference (cm) 115.2±14.7 -6.3 115.8±14.7 -4.9 -1.34 -5.06; 2.37 0.47 
Percent body fat 42.5±5.5 -3.1 43.5±6.3 -1.5 -1.38 -2.91; 0.15 0.08 
Systolic blood pressure 
(mmHg) 
125.4±15.1 -4.0 129.6±17.5 -2.6 -3.11 -9.28; 3.07 0.32 
Diastolic blood pressure 
(mmHg) 
79.9±13.2 -2.3 80.7±8.2 -1.1 -1.03 -5.59; 3.53 0.65 
Fasting glucose (mg/dL) 92.0±19.4 -2.3 91.5±18.3 +0.3 -1.17 -8.18; 5.84 0.74 
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Glycated hemoglobin 
(mmol/mol) 
39.0±6.7 -2.7 38.4±6.7 -1.8 -0.33 -2.3; 1.64 0.74 
Fasting insulin (μU/mL) 14.0 (10.2) -3.7 15.3 (12.8) -1.5 -1.50 -4.44; 1.43 0.31 
HOMA-IR 
(mmol/l*µU/mL) 
3.3 (2.2) -1.1 3.5 (2.6) -0.4 -0.44 -1.26; 0.39 0.30 
CRP (mg/L) 2.2 (3.0) -3.5 3.7 (6.0) -0.7 -2.55 -3.80; -1.31 <0.001 
Total cholesterol (mg/dL) 180.9±31.3 -5.3 182.7±33.5 -2.8 -2.07 -14.0; 9.81 0.73 
HDL-cholesterol (mg/dL) 53.3±13.3 +4.0 50.9±15.6 +4.9 -0.48 -4.05; 3.09 0.79 
Triglycerides (mg/dL) 94.5 (41.5) -10.0 91.5 (32.0) -21.6 9.14 -3.61; 21.9 0.16 
Satiety score 80 (30) +19.3 50 (60) -1.4 19.2 7.71; 30.6 0.001 
EuroQoL VAS 73.4±13.7 11.9 66.9±18.2 3.7 6.90 0.63; 13.2 0.03 
EuroQoL health status 0.77±0.13 0.11 0.69±0.21 -0.02 0.09 0.02; 0.16 0.01 
 
 
Mean ± SD, median (interquartile range) 
Delta= end-of the trial value – baseline value  
*Adjusted for stratification variables (age, gender, BMI) and the baseline value of the variable.  
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Figure legends 
 
Figure 1 
Flow of the study 
 
 
 
